Abstract

Infection by novel coronavirus SARS-CoV-2 causes different presentations of COVID-19 and some patients may progress to a critical, fatal form of the disease that requires their admission to ICU and invasive mechanical ventilation. In order to predict in advance which patients could be more susceptible to develop a critical form of COVID-19, it is essential to define the most adequate biomarkers. In this study, we analyzed several parameters related to the cellular immune response in blood samples from 109 patients with different presentations of COVID-19 who were recruited in Hospitals and Primary Healthcare Centers in Madrid, Spain, during the first pandemic peak between April and June 2020. Hospitalized patients with the most severe forms of COVID-19 showed a potent inflammatory response that was not translated into an efficient immune response. Despite the high levels of effector cytotoxic cell populations such as NK, NKT and CD8+ T cells, they displayed immune exhaustion markers and poor cytotoxic functionality against target cells infected with pseudotyped SARS-CoV-2 or cells lacking MHC class I molecules. Moreover, patients with critical COVID-19 showed low levels of the highly cytotoxic TCRγδ+ CD8+ T cell subpopulation. Conversely, CD4 count was greatly reduced in association to high levels of Tregs, low plasma IL-2 and impaired Th1 differentiation. The relative importance of these immunological parameters to predict COVID-19 severity was analyzed by Random Forest algorithm and we concluded that the most important features were related to an efficient cytotoxic response. Therefore, efforts to fight against SARS-CoV-2 infection should be focused not only to decrease the disproportionate inflammatory response, but also to elicit an efficient cytotoxic response against the infected cells and to reduce viral replication.

Highlights

  • The novel coronavirus named as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in late 2019 and it is responsible for one of the biggest pandemics in the recent History [1]

  • Thirteen percent of severe and critical patients developed disseminated intravascular coagulation (DIC), but this coagulopathy was not observed in patients with mild COVID-19

  • Patients with severe COVID-19 were not admitted to Intensive Care Unit (ICU); the median ICU stay for patients with critical COVID-19 was 48 days (IQR 20.5 to 62.0 days)

Read more

Summary

Introduction

The novel coronavirus named as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in late 2019 and it is responsible for one of the biggest pandemics in the recent History [1]. SARS-CoV-2 is a single-stranded RNA virus that causes coronavirus disease 2019 (COVID-19) It was firstly described in December 2019, when several cases of an atypical pneumonia with unknown origin were described in Wuhan (Hubei Province, China) [2]. This is the third coronavirus with pandemic potential that spreads through the world population since 2002, when a contagious infectious respiratory disease was reported in Guangdong (China) [3]. This first SARS pandemic was caused by a new coronavirus termed SARS-CoV that showed no genetic relationship with any known human coronaviruses [4, 5]. SARS-CoV-2 has been shown to be superior to other coronaviruses in its rapid growth and high capacity for dissemination within the population [7]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call